Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Jacot

Showing results (171-180 of 196) with videos related to

Pageof 20
Sort By:
JAMA Oncology|November 5, 2020
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical TrialFrançois-Clément Bidard, William Jacot, Nicolas Kiavue, et al.
British Journal of Cancer|November 14, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohortAmélie Darlix, Guillaume Louvel, Julien Fraisse, et al.
Scientific Reports|July 3, 2020
Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancerLidia Delrieu, Emmanuelle Jacquet, Céline Segura-Ferlay, et al.
NPJ Breast Cancer|September 10, 2021
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancerAmanda Bortolini Silveira, François-Clément Bidard, Marie-Laure Tanguy, et al.
Breast (Edinburgh, Scotland)|May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.
Nature Medicine|October 8, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trialShanu Modi, William Jacot, Hiroji Iwata, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2023
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohortThomas Grinda, Alison Antoine, William Jacot, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2020
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016Elise Deluche, Alison Antoine, Thomas Bachelot, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2019
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohortDavid Pasquier, Amélie Darlix, Guillaume Louvel, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohortElisa Gobbini, Monia Ezzalfani, Véronique Dieras, et al.
Pageof 20

Showing results (171-180 of 196) with videos related to

Sort By:
Pageof 20
JAMA Oncology|November 5, 2020
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical TrialFrançois-Clément Bidard, William Jacot, Nicolas Kiavue, et al.
British Journal of Cancer|November 14, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohortAmélie Darlix, Guillaume Louvel, Julien Fraisse, et al.
Scientific Reports|July 3, 2020
Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancerLidia Delrieu, Emmanuelle Jacquet, Céline Segura-Ferlay, et al.
NPJ Breast Cancer|September 10, 2021
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancerAmanda Bortolini Silveira, François-Clément Bidard, Marie-Laure Tanguy, et al.
Breast (Edinburgh, Scotland)|May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.
Nature Medicine|October 8, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trialShanu Modi, William Jacot, Hiroji Iwata, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2023
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohortThomas Grinda, Alison Antoine, William Jacot, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2020
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016Elise Deluche, Alison Antoine, Thomas Bachelot, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2019
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohortDavid Pasquier, Amélie Darlix, Guillaume Louvel, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohortElisa Gobbini, Monia Ezzalfani, Véronique Dieras, et al.
Pageof 20